SCHEMBL11973451

SCHEMBL11973451

O=[N+]([O-])c1ccccc1S(=O)(=O)Nc1cccc2scnc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFKBIA P25963 4/20 0.64
▸ RELA Q04206 4/20 0.64
▸ MEN1 O00255 4/20 0.64
▸ KMT2A Q03164 4/20 0.64
▸ SLC40A1 Q9NP59 4/20 0.64
▸ OPRK1 P41145 2/20 0.64
▸ TDP1 Q9NUW8 2/20 0.64
▸ MDM4 O15151 1/20 0.64
▸ MDM2 Q00987 1/20 0.64
▸ PKM P14618 1/20 0.52
▸ SLC10A6 Q3KNW5 1/20 0.49
▸ AGTR1 P30556 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ MMP1 P03956 1/20 0.47
▸ MMP2 P08253 1/20 0.47
▸ MMP9 P14780 1/20 0.47
▸ MMP8 P22894 1/20 0.47
▸ MMP13 P45452 1/20 0.47
▸ NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11973406 0.80 SLC40A1 (0.61) NFKBIARELAMEN1KMT2ASLC40A1
SCHEMBL11973295 0.78 SLC40A1 (1.00) NFKBIARELAMEN1KMT2ASLC40A1
SCHEMBL11973610 0.78 NFKBIA (0.74) NFKBIARELAMEN1KMT2ASLC40A1
SCHEMBL12475044 0.77 SLC40A1 (0.57) NFKBIAMEN1KMT2ASLC40A1TDP1
SCHEMBL7777578 0.76 PDE10A (0.50) MEN1KMT2ATDP1GAASMN1; SMN2
SCHEMBL11972815 0.74 SLC40A1 (0.68) NFKBIARELAMEN1KMT2ASLC40A1
SCHEMBL11972939 0.74 RELA (1.00) NFKBIARELAMEN1KMT2ASLC40A1
SCHEMBL11973574 0.74 RELA (0.75) NFKBIARELAMEN1KMT2ASLC40A1
SCHEMBL7451030 0.74 PKM (0.64) NFKBIARELAMEN1KMT2ASLC40A1
SCHEMBL5937374 0.73 SLC40A1 (0.70) NFKBIARELAMEN1KMT2ASLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 NFKBIA 277/4885RELA 1102/4885MEN1 2680/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 NFKBIA 277/4885RELA 1102/4885MEN1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback